Meta-Analysishigh evidence
Intravaginal dehydroepiandrosterone for the treatment of vulvovaginal atrophy: a systematic review and meta-analysis.
Menopause (New York, N.Y.)·July 1, 2026·PMID 41589851
Why it mattersVulvovaginal atrophy is a prevalent and bothersome component of genitourinary syndrome of menopause, often undertreated. Intravaginal DHEA offers a locally acting, non-estrogen option that improves both vaginal dryness and dyspareunia, addressing key symptoms that impact sexual health and quality of life.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled